{"id":"cefalotin","rwe":[{"pmid":"41311497","year":"2025","title":"Regulatory relationships among aldB, ampH, and acoR and their impact on β-lactam susceptibility in Phytobacter diazotrophicus.","finding":"","journal":"Frontiers in microbiology","studyType":"Clinical Study"},{"pmid":"41206063","year":"2026","title":"Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction.","finding":"","journal":"The Journal of antimicrobial chemotherapy","studyType":"Clinical Study"},{"pmid":"40959322","year":"2025","title":"A Unique Case of Aeromonas salmonicida Peritonitis in a Patient Undergoing Peritoneal Dialysis in Mexico.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"40930792","year":"2025","title":"Cephalothin, a First-Generation Cephem Antibiotic, Works as a Potent Inducer of Parthanatos.","finding":"","journal":"Biological & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"40384802","year":"2025","title":"Klebsiella pneumoniae Isolates from the Intensive Care Unit at South Qunfudah Hospital in Saudi Arabia: An Emerging Antimicrobial Resistance Profile.","finding":"","journal":"Infection and drug resistance","studyType":"Clinical Study"}],"tags":[{"label":"cefalotin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 22 member 8","category":"target"},{"label":"SLC22A8","category":"gene"},{"label":"SLC22A11","category":"gene"},{"label":"PTPN7","category":"gene"},{"label":"J01DB03","category":"atc"},{"label":"Active","category":"status"},{"label":"Bacterial infection due to Klebsiella pneumoniae","category":"indication"},{"label":"Bacterial septicemia","category":"indication"},{"label":"Female genital tract infection","category":"indication"},{"label":"Genitourinary Tract Infections","category":"indication"},{"label":"Haemophilus influenzae pneumonia","category":"indication"},{"label":"Infection of bone","category":"indication"},{"label":"Lilly","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Eli Lilly","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=cefalotin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:28:04.844635+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:28:13.927754+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cefalotin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:28:14.645097+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL617/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:28:15.149163+00:00"}},"allNames":"cephalotin","offLabel":[],"synonyms":["cefalotin sodium","cephalothin sodium","cephalothin","cefalotin","cephalotin","cephalothin sodium salt"],"timeline":[{"date":"1974-12-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Lilly)"}],"aiSummary":"Cephalotin, also known as cefalotin, is a small molecule antibiotic developed by Lilly and approved by the FDA in 1974. It targets the solute carrier family 22 member 8 and is used to treat various bacterial infections, including those caused by Klebsiella pneumoniae and Haemophilus influenzae. Cephalotin is a cephalosporin antibiotic, which works by inhibiting bacterial cell wall synthesis. It is currently owned by Lilly and has been used to treat a range of infections, including septicemia, genitourinary tract infections, and skin infections. Key safety considerations include its short half-life and low bioavailability.","brandName":"Cephalotin","ecosystem":[{"indication":"Bacterial infection due to Klebsiella pneumoniae","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Bacterial septicemia","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"}],"globalPrevalence":null},{"indication":"Female genital tract infection","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"cefotaxime","slug":"cefotaxime","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Genitourinary Tract Infections","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefazolin","slug":"cefazolin","company":"Glaxosmithkline"},{"name":"mezlocillin","slug":"mezlocillin","company":""}],"globalPrevalence":null},{"indication":"Haemophilus influenzae pneumonia","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Infection of bone","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Infection of skin AND/OR subcutaneous tissue","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Infectious disorder of joint","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"cefalexin","slug":"cefalexin","company":"Shionogi Inc"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"}],"globalPrevalence":null}],"mechanism":{"target":"Solute carrier family 22 member 8","novelty":"Follow-on","targets":[{"gene":"SLC22A8","source":"DrugCentral","target":"Solute carrier family 22 member 8","protein":"Solute carrier family 22 member 8"},{"gene":"SLC22A11","source":"DrugCentral","target":"Solute carrier family 22 member 11","protein":"Solute carrier family 22 member 11"},{"gene":"PTPN7","source":"DrugCentral","target":"Tyrosine-protein phosphatase non-receptor type 7","protein":"Tyrosine-protein phosphatase non-receptor type 7"},{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"},{"gene":"MMP9","source":"DrugCentral","target":"Matrix metalloproteinase-9","protein":"Matrix metalloproteinase-9"},{"gene":"SSTR4","source":"DrugCentral","target":"Somatostatin receptor type 4","protein":"Somatostatin receptor type 4"}],"modality":"Small Molecule","drugClass":"cefalotin","explanation":"","oneSentence":"","technicalDetail":"Cephalotin exerts its antibacterial effect by inhibiting the transpeptidase enzyme, which is essential for the cross-linking of peptidoglycan in the bacterial cell wall, ultimately leading to cell lysis and death."},"commercial":{"launchDate":"1974","_launchSource":"DrugCentral (FDA 1974-12-18, LILLY)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/574","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=cefalotin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cefalotin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:17:19.441595","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:28:17.084158+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cefalexin","drugSlug":"cefalexin","fdaApproval":"1971-01-04","relationship":"same-class"},{"drugName":"cefazolin","drugSlug":"cefazolin","fdaApproval":"1973-10-04","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefadroxil","drugSlug":"cefadroxil","fdaApproval":"1978-02-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-class"},{"drugName":"cefradine","drugSlug":"cefradine","fdaApproval":"1974-08-19","relationship":"same-class"}],"genericName":"cefalotin","indications":{"approved":[{"name":"Bacterial infection due to Klebsiella pneumoniae","source":"DrugCentral","snomedId":186435004,"regulator":"FDA"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA"},{"name":"Female genital tract infection","source":"DrugCentral","snomedId":125585007,"regulator":"FDA"},{"name":"Genitourinary Tract Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus influenzae pneumonia","source":"DrugCentral","snomedId":70036007,"regulator":"FDA"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA"},{"name":"Lower respiratory tract infection","source":"DrugCentral","snomedId":50417007,"regulator":"FDA"},{"name":"Pneumonia","source":"DrugCentral","snomedId":233604007,"regulator":"FDA"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA"},{"name":"Prevention of Perioperative Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Urinary tract infectious disease","source":"DrugCentral","snomedId":68566005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cefalexin","brandName":"cefalexin","genericName":"cefalexin","approvalYear":"1971","relationship":"same-class"},{"drugId":"cefazolin","brandName":"cefazolin","genericName":"cefazolin","approvalYear":"1973","relationship":"same-class"},{"drugId":"cefadroxil","brandName":"cefadroxil","genericName":"cefadroxil","approvalYear":"1978","relationship":"same-class"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-class"},{"drugId":"cefradine","brandName":"cefradine","genericName":"cefradine","approvalYear":"1974","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":["Cystitis"],"enrollment":81,"completionDate":"2014-07"},{"nctId":"NCT03324854","phase":"NA","title":"Use of Mosquito Net Mesh for Ventral Hernia Repair","status":"UNKNOWN","sponsor":"Hospital Central \"Dr. Ignacio Morones Prieto\"","startDate":"2016-07-01","conditions":["Hernia, Ventral","Ventral Incisional Hernia"],"enrollment":20,"completionDate":"2018-03-30"},{"nctId":"NCT01770769","phase":"NA","title":"Undisplaced Femoral Neck Fractures in the Elderly: A Trial Comparing Internal Fixation to Hemiarthroplasty","status":"UNKNOWN","sponsor":"University Hospital, Akershus","startDate":"2012-02-06","conditions":["Femoral Neck Fractures"],"enrollment":220,"completionDate":"2020-02-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000178975","MMSL":"3072","NDDF":"002712","UNII":"C22G6EYP8B","VUID":"4017538","CHEBI":"CHEBI:124991","VANDF":"4017538","INN_ID":"1477","RXNORM":"2236","UMLSCUI":"C0007735","chemblId":"CHEMBL617","ChEMBL_ID":"CHEMBL1632","KEGG_DRUG":"D00907","DRUGBANK_ID":"DB00456","PDB_CHEM_ID":" CLS","PUBCHEM_CID":"6024","SNOMEDCT_US":"373485007","IUPHAR_LIGAND_ID":"8798","SECONDARY_CAS_RN":"58-71-9","MESH_DESCRIPTOR_UI":"D002512"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1974-","companyName":"Eli Lilly","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.95 hours","clearance":"1.8 mL/min/kg","bioavailability":"0%","fractionUnbound":"0.22%","volumeOfDistribution":"0.07 L/kg"},"publicationCount":192,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DB03","allCodes":["J01DB03"]},"biosimilarFilings":[],"originalDeveloper":"Lilly","recentPublications":[{"date":"2025","pmid":"41311497","title":"Regulatory relationships among aldB, ampH, and acoR and their impact on β-lactam susceptibility in Phytobacter diazotrophicus.","journal":"Frontiers in microbiology"},{"date":"2026 Jan 6","pmid":"41206063","title":"Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction.","journal":"The Journal of antimicrobial chemotherapy"},{"date":"2025 Aug","pmid":"40959322","title":"A Unique Case of Aeromonas salmonicida Peritonitis in a Patient Undergoing Peritoneal Dialysis in Mexico.","journal":"Cureus"},{"date":"2025","pmid":"40930792","title":"Cephalothin, a First-Generation Cephem Antibiotic, Works as a Potent Inducer of Parthanatos.","journal":"Biological & pharmaceutical bulletin"},{"date":"2025","pmid":"40384802","title":"Klebsiella pneumoniae Isolates from the Intensive Care Unit at South Qunfudah Hospital in Saudi Arabia: An Emerging Antimicrobial Resistance Profile.","journal":"Infection and drug resistance"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Eli Lilly","companyId":"eli-lilly","modality":"Small Molecule","firstApprovalDate":"1974","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:28:17.084158+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}